Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
C 1.44 -0.69% -0.01
NXTC closed down 0.69 percent on Monday, March 18, 2024, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -0.69%
Narrow Range Bar Range Contraction -0.69%
Wide Bands Range Expansion -0.69%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 13 hours ago
200 DMA Resistance about 15 hours ago
Fell Below 200 DMA about 15 hours ago
200 DMA Support about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NextCure, Inc. Description

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Clinical Development Cancer Treatment Tumor Virotherapy Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Oncolytics Biotech Treatment Of Ovarian Cancer Metastasis Metastatic Solid Tumors Tumor Microenvironment Halozyme Immune Related Diseases

Is NXTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.09
52 Week Low 0.98
Average Volume 166,817
200-Day Moving Average 1.42
50-Day Moving Average 1.39
20-Day Moving Average 1.61
10-Day Moving Average 1.59
Average True Range 0.14
RSI (14) 44.13
ADX 38.84
+DI 20.15
-DI 17.58
Chandelier Exit (Long, 3 ATRs) 1.68
Chandelier Exit (Short, 3 ATRs) 1.77
Upper Bollinger Bands 1.88
Lower Bollinger Band 1.34
Percent B (%b) 0.19
BandWidth 33.43
MACD Line 0.02
MACD Signal Line 0.07
MACD Histogram -0.0442
Fundamentals Value
Market Cap 40.18 Million
Num Shares 27.9 Million
EPS -2.35
Price-to-Earnings (P/E) Ratio -0.61
Price-to-Sales 9.52
Price-to-Book 0.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.50
Resistance 3 (R3) 1.50 1.48 1.49
Resistance 2 (R2) 1.48 1.46 1.48 1.49
Resistance 1 (R1) 1.46 1.46 1.47 1.46 1.48
Pivot Point 1.44 1.44 1.45 1.44 1.44
Support 1 (S1) 1.42 1.42 1.43 1.42 1.40
Support 2 (S2) 1.40 1.42 1.40 1.39
Support 3 (S3) 1.38 1.40 1.39
Support 4 (S4) 1.38